Please login to the form below

Not currently logged in
Email:
Password:

Vaccine development

This page shows the latest Vaccine development news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs mRNA flu vaccine deal with BioNTech

Pfizer signs mRNA flu vaccine deal with BioNTech

Using mRNA is an attractive proposition for flu vaccine development because its can be sued to code for “any protein or multiple proteins, and the potential to manufacture higher potency flu ... efficient at recruiting immunocompetent cells at the

Latest news

More from news
Approximately 0 fully matching, plus 103 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    Feminists pointed to the gendered nature of the vaccine, raising questions as to why only women appeared to have been considered in vaccine development, much like they have historically been in ... While the vaccine remained freely available, it was not

  • Deal Watch September 2016 Deal Watch September 2016

    up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to $125m] and Sanofi ($43.2m). ... In a similar vein Sanofi will receive $43.2m in funding for the mid stage

  • Deal Watch December 2015 Deal Watch December 2015

    409. Kyorin (JP). BMS. Collaboration, licence. Discovery, development and commercialisation of FPR 2 agonists for undisclosed indication. ... 200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of

  • Pharma deals during January 2013 Pharma deals during January 2013

    This deal is for technology development and carries a $5m non-refundable payment. . ... GSK.  JV. Combination paediatrics vaccines. Terminations. Although the active development for Cytos'NIC 002 therapeutic vaccine for smoking cessation had ceased

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... LigoCyte has a number of vaccine products in development, including its lead candidate, which is in phase I/II vaccine to prevent norovirus

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • McCann Health appoints Daniel Carucci as global medical director McCann Health appoints Daniel Carucci as global medical director

    Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health

  • Sanofi names CSO Gary Nabel to Ebola role Sanofi names CSO Gary Nabel to Ebola role

    Elias Zerhouni, president of Sanofi global research and development, said: “Given his past experience in public health epidemics as director of the NIH vaccine research centre and his leadership in developing ... He is working with other organisations,

  • Takeda appoints head of vaccines development Takeda appoints head of vaccines development

    Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza. ... development organisation and advanced vaccine development against illnesses

  • Sanofi appoints NIH’s Gary Nabel as chief scientific officer Sanofi appoints NIH’s Gary Nabel as chief scientific officer

    He previously headed vaccine research centre of the US National Institute of Allergy and Infectious Diseases. ... During this period, he provided overall direction of the VRC, including the development of notable vaccine strategies against HIV, ebola,

  • Peter Chambre joins cancer vaccine biotech Immatics Peter Chambre joins cancer vaccine biotech Immatics

    He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. ... With IMA901, Immatics' lead multi-peptide based vaccine now in phase III

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics